Bedrijfsoverzicht
Medline Inc. is a prominent manufacturer of medical-surgical products that serves a wide array of healthcare facilities, including hospitals, surgery centers, physician offices, post-acute facilities, and nursing homes across the United States and internationally. The company operates within the Healthcare sector, specifically focusing on the Medical Instruments & Supplies industry, which positions it as a critical supplier of essential consumables for patient care and clinical procedures. Its operational scale is substantial, evidenced by a market capitalization of $37.01 billion and an annual revenue of $28.43 billion, supported by a workforce of 45,000 employees. These valuation and revenue figures indicate that the company holds a significant position in the global medical supply market, suggesting robust demand for its product lines and a dominant role in distributing goods to various segments of the healthcare ecosystem.
Financiële gezondheid
The company reported a revenue of $28.43 billion and a net income of $1.16 billion over the trailing twelve months, resulting in an EBITDA of $3.19 billion. The substantial gap between the total revenue and net income reveals a cost structure where operating expenses, including cost of goods sold and overhead, consume a significant portion of top-line growth before reaching the bottom line. Medline generates a free cash flow of $791.25 million, which provides the organization with strong financial flexibility to fund operations, manage liquidity, or invest in capacity expansion without relying solely on external financing. The company's profitability is characterized by a gross margin of 26.4%, an operating margin of 5.7%, and a profit margin of 4.1%, indicating that while the business model generates revenue at a moderate markup, operational efficiency and pricing power are critical to maintaining those margins. On the balance sheet, the firm holds $1.98 billion in cash against $13.01 billion in debt, resulting in a debt-to-equity ratio of 67.47%, which suggests a highly leveraged capital structure rather than a conservative approach to financial leverage. Despite the high leverage, the current ratio stands at 4.29, indicating that the company possesses ample short-term assets relative to its short-term liabilities and maintains strong liquidity to meet obligations as they come due. Furthermore, the return on equity is 6.5% while the return on assets is 3.7%, metrics that reveal management's effectiveness in generating returns on shareholders' capital relative to the total asset base employed in the business.
Waarderingsbeoordeling
Medline Inc. is valued with a trailing P/E ratio of 31.89 and a forward P/E of 27.56, implying that the market expects earnings to increase significantly in the coming year to justify the lower multiple on forward earnings compared to the historical trailing multiple. The price-to-book ratio is 3.45, indicating that the market prices the company's equity at a significant premium over its tangible book value, reflecting intangible assets like brand reputation or distribution networks that are not captured on the balance sheet. Alternative valuation metrics such as a price-to-sales ratio of 1.30 and an EV/EBITDA of 17.74 provide additional context, suggesting that investors are willing to pay a moderate multiple relative to sales and earnings before interest, taxes, depreciation, and amortization. Regarding trading ranges, the stock has a 52-week high of $50.88 and a 52-week low of $34.89, meaning the current price sits within this historical band but is not at either extreme, reflecting recent market volatility without a definitive breakout or breakdown. The beta value is listed as N/A, which prevents a direct calculation of price volatility relative to the broader market based on standard statistical measures, though the stock's price movement is generally expected to follow broader market trends typical of large-cap healthcare stocks.
Growth & Income
Revenue growth year-over-year is recorded at 14.8%, while earnings growth year-over-year is an exceptional 1254.7%, indicating that earnings are growing at a rate vastly superior to revenue, which implies significant leverage in the company's cost structure or a one-time adjustment to income that is not yet reflected in the top line. The company does not distribute a dividend to shareholders, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which means the firm reinvests all its earnings back into the business for growth initiatives, debt reduction, or share buybacks rather than returning cash to investors. This reinvestment strategy aligns with the company's current growth profile where earnings expansion outpaces revenue expansion, allowing management to strengthen the balance sheet or acquire complementary assets to expand market share. Overall, Medline Inc. presents a growth-oriented income profile characterized by high earnings velocity and a retention of capital for internal deployment, rather than a yield-focused strategy typical of mature, cash-cow companies in the healthcare sector.